INS and metabolic syndrome: The significant improvements in glycemic control parameters (FBG, HOMA‐IR, serum insulin) and lipid profiles suggest that Sumac may be particularly beneficial for patients with insulin resistance and dyslipidemia, potentially reducing their overall cardiovascular risk burden.